Phage therapy as a renewed therapeutic approach to mycobacterial infections: a comprehensive review
- PMID: 31571947
- PMCID: PMC6756577
- DOI: 10.2147/IDR.S218638
Phage therapy as a renewed therapeutic approach to mycobacterial infections: a comprehensive review
Abstract
Mycobacterial infections are considered to a serious challenge of medicine, and the emergence of MDR and XDR tuberculosis is a serious public health problem. Tuberculosis can cause high morbidity and mortality around the world, particularly in developing countries. The emergence of drug-resistant Mycobacterium infection following limited therapeutic technologies coupled with the serious worldwide tuberculosis epidemic has adversely affected control programs, thus necessitating the study of the role bacteriophages in the treatment of mycobacterial infection. Bacteriophages are viruses that are isolated from several ecological specimens and do not exert adverse effects on patients. Phage therapy can be considered as a significant alternative to antibiotics for treating MDR and XDR mycobacterial infections. The useful ability of bacteriophages to kill Mycobacterium spp has been explored by numerous research studies that have attempted to investigate the phage therapy as a novel therapeutic/diagnosis approach to mycobacterial infections. However, there are restricted data about phage therapy for treating mycobacterial infections. This review presents comprehensive data about phage therapy in the treatment of mycobacterial infection, specifically tuberculosis disease.
Keywords: mycobacteria infection; mycobacteriophage; phage therapy; tuberculosis.
© 2019 Azimi et al.
Conflict of interest statement
All of the authors declare that there are no commercial, personal, political, and any other potential conflicting interests related to the published manuscript.
Figures








Similar articles
-
[Development of antituberculous drugs: current status and future prospects].Kekkaku. 2006 Dec;81(12):753-74. Kekkaku. 2006. PMID: 17240921 Review. Japanese.
-
Mycobacteriophages in diagnosis and alternative treatment of mycobacterial infections.Front Microbiol. 2023 Sep 28;14:1277178. doi: 10.3389/fmicb.2023.1277178. eCollection 2023. Front Microbiol. 2023. PMID: 37840750 Free PMC article. Review.
-
Bacteriophages of Mycobacterium tuberculosis, their diversity, and potential therapeutic uses: a review.BMC Infect Dis. 2022 Dec 22;22(1):957. doi: 10.1186/s12879-022-07944-9. BMC Infect Dis. 2022. PMID: 36550444 Free PMC article. Review.
-
Application of Bacteriophages for Mycobacterial Infections, from Diagnosis to Treatment.Microorganisms. 2021 Nov 16;9(11):2366. doi: 10.3390/microorganisms9112366. Microorganisms. 2021. PMID: 34835491 Free PMC article. Review.
-
A Review on Mycobacteriophages: From Classification to Applications.Pathogens. 2022 Jul 7;11(7):777. doi: 10.3390/pathogens11070777. Pathogens. 2022. PMID: 35890022 Free PMC article. Review.
Cited by
-
Looking beyond Typical Treatments for Atypical Mycobacteria.Antibiotics (Basel). 2020 Jan 3;9(1):18. doi: 10.3390/antibiotics9010018. Antibiotics (Basel). 2020. PMID: 31947883 Free PMC article. Review.
-
Mycobacterium tuberculosis Rv2617c is involved in stress response and phage infection resistance.Heliyon. 2024 Mar 5;10(5):e27400. doi: 10.1016/j.heliyon.2024.e27400. eCollection 2024 Mar 15. Heliyon. 2024. PMID: 38495141 Free PMC article.
-
Mycobacteriophages as Potential Therapeutic Agents against Drug-Resistant Tuberculosis.Int J Mol Sci. 2021 Jan 13;22(2):735. doi: 10.3390/ijms22020735. Int J Mol Sci. 2021. PMID: 33450990 Free PMC article. Review.
-
Beyond antibiotics: recent developments in the diagnosis and management of nontuberculous mycobacterial infection.Breathe (Sheff). 2022 Jun;18(2):210171. doi: 10.1183/20734735.0171-2021. Epub 2022 Jul 12. Breathe (Sheff). 2022. PMID: 36337137 Free PMC article. Review.
-
Topically Applied Bacteriophage to Control Multi-Drug Resistant Klebsiella pneumoniae Infected Wound in a Rat Model.Antibiotics (Basel). 2021 Aug 27;10(9):1048. doi: 10.3390/antibiotics10091048. Antibiotics (Basel). 2021. PMID: 34572629 Free PMC article.
References
-
- Gondil V, Chhibber S. Exploring potential of phage therapy for tuberculosis using model organism. Biomed Biotechnol Res J. 2018;2(1):9–15. doi:10.4103/bbrj.bbrj_93_17 - DOI
-
- Azimi T, Shariati A, Fallah F, et al. Mycobacterium tuberculosis genotyping using MIRU-VNTR typing. J Mazandaran Univ Med Sci. 2017;27(149):40–48.
-
- WHO. Global Tuberculosis Report 2018. World Health Organization; 2018.
LinkOut - more resources
Full Text Sources
Miscellaneous